Drug intelligence / Profile preview

Shufeng Wenfei Zhike

Development stage: Unknown
Lead developer: Guangzhou Yuekang Biopharmaceutical
Administration: Oral

Overview

Shufeng Wenfei Zhike is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Oriental Hospital of Beijing University of Traditional Chinese Medicine. Formulated as a granule, it is primarily investigated for the treatment of cough variant asthma (CVA). The preparation is designed according to TCM principles to 'disperse wind' (Shufeng), 'warm the lungs' (Wenfei), and 'relieve cough' (Zhike), targeting the symptomatic and underlying patterns of wind-cold lung invasion. Clinical research, including trial ChiCTR2000029686, focuses on evaluating its efficacy in reducing cough frequency, improving airway hyperresponsiveness, and ensuring safety in patients with CVA.

Other names: Shufeng Wenfei Zhike granule疏风温肺止咳颗粒

Beyond the preview

Go deeper on Shufeng Wenfei Zhike.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shufeng Wenfei Zhike.

Explore the full profile